Product Liability Update: April 2016

Foley Hoag LLP

Massachusetts Superior Court Rejects “Innovator Liability” Failureto-Warn Claim, Holds Branded Pharmaceutical Manufacturer Owed No Duty to Plaintiff Alleging Injury From Equivalent Generic Drug That Copied Defendant’s Labeling But Defendant Did Not Make Or Sell -

In Rafferty v. Merck & Co., 2016 Mass. Super. LEXIS 48 (Mass. Super. Ct. May 23, 2016), plaintiff sued his prescribing physician and a pharmaceutical manufacturer for injuries allegedly suffered from use of the drug finasteride, the generic equivalent of a brand name medication manufactured by defendant. Plaintiff brought claims for negligence and violation of Mass. Gen. Laws Ch. 93A (the state’s unfair and deceptive practices statute), alleging defendant failed to warn that sexual dysfunction was a potential side effect. Defendant moved to dismiss, arguing Massachusetts does not recognize an “innovator liability” theory that would extend a brand name, i.e., innovator, drug manufacturer’s duty to warn beyond users of its product to individuals who use a generic equivalent that copies the manufacturer’s labeling.

The court acknowledged that this was an issue of first impression in Massachusetts. The court noted that the federal Food, Drug and Cosmetics Act (“FDCA”) established an “onerous and lengthy” process for the approval of a new branded drug by the United States Food & Drug Administration (“FDA”), including approval of its label, while a chemically and biologically equivalent generic drug may be approved through an abbreviated process so long as its label follows that of the branded drug. And under the United States Supreme Court’s rulings in PLIVA, Inc. v. Mensing, 564 U.S. 604, 613 (2011) (see July 2011 Foley Hoag Product Liability Update), and Mut. Pharm. Co. v. Bartlett, 133 S. Ct. 2466, 2476 (2013) (see July 2013 Foley Hoag Product Liability Update), failure-to-warn and design defect claims against generic manufacturers are preempted because the FDCA prohibits the manufacturer from departing from the FDA-approved branded drug’s design and labeling, leaving the branded manufacturer as the only possible defendant.

Please see full Update below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley Hoag LLP | Attorney Advertising

Written by:

Foley Hoag LLP

Foley Hoag LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.